Do you regain weight after stopping Mounjaro?

What happened in clinical trials when tirzepatide was stopped

The clearest evidence comes from the SURMOUNT-4 trial, which enrolled adults who had already lost weight on tirzepatide and then randomised them to either continue the medicine or switch to placebo. Those who continued treatment maintained their weight loss; those who switched to placebo regained around two-thirds of what they had lost over the following year, even though both groups stayed in a structured lifestyle programme. The trial, published in the Journal of the American Medical Association, made it plain: for most people, the weight lost on tirzepatide tracks closely with continuing to take it.

NICE's appraisal of tirzepatide (NICE technology appraisal TA1026) acknowledges this rebound pattern when discussing long-term use and cost-effectiveness. This is not a side effect unique to Mounjaro. The same trajectory appears across the GLP-1 class and is a feature of how these medicines interact with the body's weight-regulation systems.

The practical takeaway: the question is rarely whether to stop, but when and how, and that is a clinical conversation, not a self-managed one. If you are thinking through your options, our overview of tirzepatide weight regain goes into further detail on the mechanisms involved.

Why the body regains weight, the biology behind the rebound

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, which together reduce appetite, slow gastric emptying and influence how the brain registers fullness. While you are taking the medicine, those signals are reinforced artificially. Stop the medicine and those reinforced signals stop with it.

What happens next is well-documented in obesity medicine. Hunger hormones (particularly ghrelin) climb back toward their pre-treatment levels. The brain's reward response to food recalibrates. Metabolic rate, which may have adjusted downward during rapid weight loss, does not simply spring back upward when eating resumes. The result is a convergence of increased appetite, reduced satiety and a body primed to restore its previous weight. It is the same pattern seen after any significant calorie-restricted period, amplified by the speed and degree of loss that tirzepatide produces.

Understanding this matters because it reframes the question. Stopping Mounjaro after reaching a target is not a finish line; it is the start of a different phase of weight management. The strategies for keeping weight off after stopping Mounjaro are quite specific, and building them before you stop is considerably more effective than scrambling afterward.

How much weight comes back, and how quickly

Speed and scale depend on several factors: how long you were on treatment, which dose you reached, how much you lost, and what lifestyle habits you built alongside the medicine. In SURMOUNT-4, the placebo group had regained around 14 percentage points of body weight within 36 weeks of stopping. Other analyses of GLP-1 discontinuation suggest that roughly half of lost weight returns within 12 months in most people without ongoing intervention.

That said, regain is not uniform. People who used the treatment period to meaningfully shift their eating patterns and physical activity tend to regain more slowly. A smaller group (those who lost weight very gradually, built substantial muscle mass through resistance training, and addressed the behavioural factors around eating) maintain more of their loss for longer. But these are the exception, and relying on willpower alone after stopping a medicine that was doing heavy hormonal lifting is asking a lot.

If you want a realistic sense of the timescale involved in your own situation, if you read about how weight regain after Mounjaro typically unfolds alongside your prescriber's view you will be better placed to plan ahead. On a related note, it is also worth understanding the cost picture before making decisions: our treatment overview page shows what private Mounjaro treatment through a clinically reviewed service includes.

Planning ahead: what prescribers typically consider

A well-structured stop is different from simply running out of pens and not reordering. Prescribers thinking about discontinuation typically weigh several things: how much weight was lost, whether the comorbidities that triggered treatment have improved, what maintenance strategies are in place, and whether the patient has the support structures to sustain the lifestyle changes made during treatment.

Gradual dose reduction rather than an abrupt stop is often discussed, though evidence on whether tapering meaningfully reduces regain is still limited. The NHS's published guidance on weight management injections emphasises that these medicines work best as part of a broader programme, and that stopping is a clinical decision, not an administrative one.

If you ordered through a registered pharmacy and treatment arrived in the plain, untracked packaging that services like ours use, that discretion is easy to maintain through a planned stop too. What is less easy is making that call without clinical input. If you are also still in the early stages of treatment, our guide on how long Mounjaro takes to work can help you set realistic expectations before you consider any changes. There is a detailed look at maintaining weight loss after stopping Mounjaro that covers the practical steps prescribers tend to recommend. And if you are weighing up whether stopping is the right move at all, our page on weight regain after stopping tirzepatide sets out what the evidence suggests you can realistically expect, which is a useful starting point before speaking to our prescribers.